nach oben

Immunologic Research

Erschienen in:

24.05.2022 | Review

Potential therapeutic strategies for myocardial infarction: the role of Toll-like receptors

verfasst von: Sumra Komal, Nimrah Komal, Ali Mujtaba, Shu-Hui Wang, Li-Rong Zhang, Sheng-Na Han

Erschienen in: Immunologic Research | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Myocardial infarction (MI) is a life-threatening condition among patients with cardiovascular diseases. MI increases the risk of stroke and heart failure and is a leading cause of morbidity and mortality worldwide. Several genetic and epigenetic factors contribute to the development of MI, suggesting that further understanding of the pathomechanism of MI might help in the early management and treatment of this disease. Toll-like receptors (TLRs) are well-known members of the pattern recognition receptor (PRR) family and contribute to both adaptive and innate immunity. Collectively, studies suggest that TLRs have a cardioprotective effect. However, prolonged TLR activation in the response to signals generated by damage-associated molecular patterns (DAMPs) results in the release of inflammatory cytokines and contributes to the development and exacerbation of myocardial inflammation, MI, ischemia–reperfusion injury, myocarditis, and heart failure. The objective of this review is to discuss and summarize the association of TLRs with MI, highlighting their therapeutic potential for the development of advanced TLR-targeted therapies for MI.

Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, Lisheng L. Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction. World Health Organization Definition of Myocardial Infarction: 2008–09 Revision. Int J Epidemiol. 2011;40(1):139–46. https://doi.org/10.1093/ije/dyq165.CrossRefPubMed

Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, Rosal M, Yancy CW. Social determinants of risk and outcomes for cardiovascular disease. Circulation. 2015;132(9):873–98. https://doi.org/10.1161/CIR.0000000000000228.CrossRefPubMed

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, De Ferranti SD, Floyd J, Fornage M, Gillespie C. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.PubMedPubMedCentralCrossRef

Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, Sumitsuji S, Kawano S, Ueda Y, Hamasaki T. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2012, CJ-11.

Kim HO, Kim JM, Woo JS, Beom Park C, Man Cho J, Lee SU, Kim CJ, Jeong MH, Kim W, KAMIR Investigators. Circadian distribution of acute myocardial infarction in different age groups. Am J Cardiol. 2018;121(11):1279–84.PubMedCrossRef

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.PubMedPubMedCentralCrossRef

Gianfagna F, Cugino D, Santimone I, Iacoviello L. From candidate gene to genome-wide association studies in cardiovascular disease. Thromb Res. 2012;129(3):320–4.PubMedCrossRef

Yamada Y, Kato K, Oguri M, Horibe H, Fujimaki T, Yasukochi Y, Takeuchi I, Sakuma J. Identification of 13 novel susceptibility loci for early-onset myocardial infarction, hypertension, or chronic kidney disease. Int J Mol Med. 2018;42(5):2415–36.PubMedPubMedCentral

Bagai A, Dangas GD, Stone GW, Granger CB. Reperfusion strategies in acute coronary syndromes. Circ Res. 2014;114(12):1918–28.PubMedCrossRef

10.

Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, Boveda S, Kacet S, Mabo P, Barnay C. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J. 2014;35(2):116–22.PubMedCrossRef

11.

Wu, X.; Iroegbu, C. D.; Peng, J.; Guo, J.; Yang, J.; Fan, C. Cell death and exosomes regulation after myocardial infarction and ischemia-reperfusion. Front Cell Dev Biol. 2021, 9. https://doi.org/10.3389/fcell.2021.673677.

12.

Bu D, Su Z, Zou J, Meng M, Wang C. Study of the mechanism underlying therapeutic effect of compound longmaining on myocardial infarction using a network pharmacology-based approach. Biomed Pharmacother. 2019;118: 109234.PubMedCrossRef

13.

Lemaitre B, Nicolas E, Michaut L, Reichhart J-M, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86(6):973–83.PubMedCrossRef

14.

Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Network 2018;18 (4).

15.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–84.PubMedCrossRef

16.

Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA. An essential role of the NF-ΚB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001;166(12):7128–35.PubMedCrossRef

17.

Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG DsDNA. Immunity. 2003;19(6):837–47.PubMedCrossRef

18.

Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202(9):1171–7.PubMedPubMedCentralCrossRef

19.

Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, Hogaboam CM, Kunkel SL. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205(11):2609–21.PubMedPubMedCentralCrossRef

20.

Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med. 2006;12(4):167–76.PubMedCrossRef

21.

Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H, Wagner H. Endocytosed HSP60s Use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem. 2001;276(33):31332–9.PubMedCrossRef

22.

Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277(17):15107–12.PubMedCrossRef

23.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.PubMedCrossRef

24.

Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–96.PubMedCrossRef

25.

Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009;183(1):27–31.PubMedCrossRef

26.

Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276(13):10229–33.PubMedCrossRef

27.

Tesar BM, Jiang D, Liang J, Palmer SM, Noble PW, Goldstein DR. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant. 2006;6(11):2622–35.PubMedCrossRef

28.

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–9.PubMedCrossRef

29.

Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Investig. 2005;115(8):2223–33.PubMedPubMedCentralCrossRef

30.

Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol. 2001;167(5):2887–94.PubMedCrossRef

31.

Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168(10):5233–9.PubMedCrossRef

32.

Yu L, Wang L, Chen S. Endogenous Toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14(11):2592–603.PubMedPubMedCentralCrossRef

33.

Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, Hoshino K, Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167(10):5887–94.PubMedCrossRef

34.

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science. 2004;303(5663):1526–9.PubMedCrossRef

35.

Hayashi F, Smith KD, Ozinsky A, Hawn TR, Eugene CY, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410(6832):1099–103.PubMedCrossRef

36.

Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108(23):2905–10.PubMedCrossRef

37.

Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor ΚB by oxidative stress in cardiac myocytes. J Biol Chem. 2001;276(7):5197–203.PubMedCrossRef

38.

Wang L, Li Y-L, Zhang C-C, Cui W, Wang X, Xia Y, Du J, Li H-H. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2014;101(3):383–92.PubMedCrossRef

39.

Wu RN, Yu TY, Zhou JC, Li M, Gao HK, Zhao C, Dong RQ, Peng D, Hu ZW, Zhang XW, Wu YQ. Targeting HMGB1 ameliorates cardiac fibrosis through restoring TLR2-mediated autophagy suppression in myocardial fibroblasts. Int J Cardiol. 2018;267:156–62. https://doi.org/10.1016/j.ijcard.2018.04.103.CrossRefPubMed

40.

Wang JW, Fontes MS, Wang X, Chong SY, Kessler EL, Zhang YN, D Haan JJ, Arslan F, De Jager SC, Timmers L, Van Veen TA. Leukocytic toll like receptor 2 deficiency preserves cardiac function and reduces fibrosis in sustained pressure overload. Sci Rep. 2017;7(1):1. https://doi.org/10.1038/s41598017-09451-3.CrossRefPubMedPubMedCentral

41.

Arslan F, Smeets MB, O’Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti–toll-like receptor-2 antibody. Circulation. 2010;121(1):80–90. https://doi.org/10.1161/CIRCULATIONAHA.109.880187.CrossRefPubMed

42.

Selejan S, Pöss J, Walter F, Hohl M, Kaiser R, Kazakov A, Böhm M, Link A. Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock. Eur Heart J. 2012;33(9):1085–94.PubMedCrossRef

43.

Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Frøland SS, Mollnes TE, Dickstein K, Aukrust P. Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. J Cardiac Fail. 2006;12(8):659–63. https://doi.org/10.1016/j.cardfail.2006.07.002.CrossRef

44.

Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, Kao RL, Williams DL, Gao X, Li C. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2010;87(4):694–703. https://doi.org/10.1093/cvr/cvq116.CrossRefPubMedPubMedCentral

45.

Kumar S, Sunagar R, Gosselin E. Bacterial protein Toll-like-receptor agonists: a novel perspective on vaccine adjuvants. Front Immunol. 2019;10:1144.PubMedPubMedCentralCrossRef

46.

Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-ΚB dependent inflammatory response. Cardiovasc Res. 2006;72(3):384–93.PubMedCrossRef

47.

Arslan F, Smeets MB, O’Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G. Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti–Toll-like receptor-2 antibody. Circulation. 2010;121(1):80–90.PubMedCrossRef

48.

Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC. Preconditioning by Toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med. 2010;38(3):903–9.PubMedCrossRef

49.

Dong J-W, Vallejo JG, Tzeng H-P, Thomas JA, Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol. 2010;298(3):H1079–87.PubMedPubMedCentralCrossRef

50.

Wang X, Ha T, Liu L, Hu Y, Kao R, Kalbfleisch J, Williams D, Li C. TLR3 mediates repair and regeneration of damaged neonatal heart through glycolysis dependent YAP1 regulated MiR-152 expression. Cell Death Differ. 2018;25(5):966–82.PubMedPubMedCentralCrossRef

51.

Chen C, Feng Y, Zou L, Wang L, Chen HH, Cai J-Y, Xu J-M, Sosnovik DE, Chao W. Role of extracellular RNA and TLR 3-Trif signaling in myocardial ischemia–reperfusion injury. J Am Heart Assoc. 2014;3(1): e000683.PubMedPubMedCentralCrossRef

52.

Gao T, Zhang S-P, Wang J-F, Liu L, Wang Y, Cao Z-Y, Hu Q-K, Yuan W-J, Lin L. TLR3 contributes to persistent autophagy and heart failure in mice after myocardial infarction. J Cell Mol Med. 2018;22(1):395–408.PubMedCrossRef

53.

Lu C, Ren D, Wang X, Ha T, Liu L, Lee EJ, Hu J, Kalbfleisch J, Gao X, Kao R. Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury. Biochim Biophys Acta (BBA) - Mol Basis Dis 2014;1842(1):22–31.

54.

Chen E, Chen C, Niu Z, Gan L, Wang Q, Li M, Cai X, Gao R, Katakam S, Chen H, Zhang S. Poly (I: C) preconditioning protects the heart against myocardial ischemia/reperfusion injury through TLR3/PI3K/Akt-dependent pathway. Signal Transduct Target Ther. 2020;5(1):1–15.CrossRef

55.

Wu B, Ni H, Li J, Zhuang X, Zhang J, Qi Z, Chen Q, Wen Z, Shi H, Luo X, Jin B. The impact of circulating mitochondrial DNA on cardiomyocyte apoptosis and myocardial injury after TLR4 activation in experimental autoimmune myocarditis. Cell Physiol Biochem. 2017;42(2):713–28. https://doi.org/10.1159/000477889.CrossRefPubMed

56.

Jenke A, Wilk S, Poller W, Eriksson U, Valaperti A, Rauch BH, Stroux A, Liu P, Schultheiss H-P, Scheibenbogen C, Skurk C. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res. 2013;99(3):422–31. https://doi.org/10.1093/cvr/cvt118.CrossRefPubMed

57.

Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, Hiramori K, Nakamura M. Activated Toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol. 2006;109(2):226–34.PubMedCrossRef

58.

Yang J, Jin L, Ding J, Zhou Y, Yang J. Expression of Toll-like receptor 4 on peripheral blood mononuclear cells and its effects on patients with acute myocardial infarction treated with thrombolysis. Arch Med Res. 2010;41(6):423–9.PubMedCrossRef

59.

Frangogiannis NG, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, Entman ML. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998;98(7):687–98.PubMedCrossRef

60.

Yang R, Song Z, Wu S, Wei Z, Xu Y, Shen X. Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model. Atherosclerosis. 2018;279:23–31.PubMedCrossRef

61.

Liu L, Wang Y, Cao Z-Y, Wang M-M, Liu X-M, Gao T, Hu Q-K, Yuan W-J, Lin L. Up-regulated TLR 4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015;19(12):2728–40.PubMedPubMedCentralCrossRef

62.

Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(1_supplement):I–270.CrossRef

63.

Maekawa Y, Mizue N, Chan A, Shi Y, Liu Y, Dawood S, Chen M, Dawood F, De Couto G, Li GH. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation. 2009;120(14):1401–14.PubMedCrossRef

64.

Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008;295(3):H1311–8.PubMedPubMedCentralCrossRef

65.

Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660–7.PubMedPubMedCentralCrossRef

66.

Wang Y, Hu H, Yin J, Shi Y, Tan J, Zheng L, Wang C, Li X, Xue M, Liu J, Wang Y. TLR4 participates in sympathetic hyperactivity post-MI in the PVN by regulating NF-κB pathway and ROS production. Redox Biol. 2019;24: 101186. https://doi.org/10.1016/j.redox.2019.101186.CrossRefPubMedPubMedCentral

67.

Fu H, Shuai W, Kong B, Jiang X, Huang H. MD1 Depletion predisposes to ventricular arrhythmias in the setting of myocardial infarction. Heart Lung Circ. 2021;30(6):869–81. https://doi.org/10.1016/j.hlc.2020.09.938.CrossRefPubMed

68.

Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, Rosenzweig A, Chao W. MyD88 and NOS2 are essential for Toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2006;291(4):H1900–9.PubMedCrossRef

69.

Zhao P, Wang J, He L, Ma H, Zhang X, Zhu X, Dolence EK, Ren J, Li J. Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med. 2009;13(8a):1513–25.PubMedPubMedCentralCrossRef

70.

Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans M-J, Doevendans PA, van Echteld CJ, Joles JA, Quax PH. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102(2):257–64.PubMedCrossRef

71.

Oyama J, Blais C, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation. 2004;109(6):784–9. https://doi.org/10.1161/01.CIR.0000112575.66565.84.CrossRefPubMed

72.

Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg. 2004;128(2):170–9. https://doi.org/10.1016/j.jtcvs.2003.11.036.CrossRefPubMed

73.

Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–7.PubMedPubMedCentralCrossRef

74.

Shintani Y, Kapoor A, Kaneko M, Smolenski RT, D’Acquisto F, Coppen SR, Harada-Shoji N, Lee HJ, Thiemermann C, Takashima S. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci. 2013;110(13):5109–14.PubMedPubMedCentralCrossRef

75.

Duerr GD, Wu S, Schneider ML, Marggraf V, Weisheit CK, Velten M, Verfuerth L, Frede S, Boehm O, Treede H, Dewald O. CpG postconditioning after reperfused myocardial infarction is associated with modulated inflammation, less apoptosis, and better left ventricular function. Am J Physiol Heart Circ Physiol. 2020;319(5):H995–1007.PubMedCrossRef

76.

Tian Y, Charles EJ, Yan Z, Wu D, French BA, Kron IL, Yang Z. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1–receptor for advanced glycation end products–Toll-like receptor 9 pathway. J Thorac Cardiovasc Surg. 2019;157(6):2256–69.PubMedCrossRef

77.

Liu F-Y, Fan D, Yang Z, Tang N, Guo Z, Ma S-Q, Ma Z-G, Wu H-M, Deng W, Tang Q-Z. TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis. Cell Death Dis. 2019;10(7):1–16.CrossRef

78.

Omiya S, Omori Y, Taneike M, Protti A, Yamaguchi O, Akira S, Shah AM, Nishida K, Otsu K. Toll-like receptor 9 prevents cardiac rupture after myocardial infarction in mice independently of inflammation. Am J Physiol Heart Circ Physiol. 2016;311(6):H1485–97.PubMedPubMedCentralCrossRef

79.

Ohm IK, Gao E, Belland Olsen M, Alfsnes K, Bliksøen M, Øgaard J, Ranheim T, Nymo SH, Holmen YD, Aukrust P, Yndestad A, Vinge LE. Toll-like receptor 9-activation during onset of myocardial ischemia does not influence infarct extension. PLoS ONE. 2014;9(8): e104407. https://doi.org/10.1371/journal.pone.0104407.CrossRefPubMedPubMedCentral

80.

Enquobahrie DA, Smith NL, Bis JC, Carty CL, Rice KM, Lumley T, Hindorff LA, Lemaitre RN, Williams MA, Siscovick DS. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol. 2008;101(12):1683–8.PubMedPubMedCentralCrossRef

81.

Blasius AL, Beutler B. Intracellular Toll-like receptors. Immunity. 2010;32(3):305–15.PubMedCrossRef

82.

Zhang S-P, Yang R-H, Shang J, Gao T, Wang R, Peng X-D, Miao X, Pan L, Yuan W-J, Lin L. FOXC1 up-regulates the expression of Toll-like receptors in myocardial ischaemia. J Cell Mol Med. 2019;23(11):7566–80.PubMedPubMedCentralCrossRef

83.

Roelofs MF, Joosten LAB, Abdollahi-Roodsaz S, van Lieshout AWT, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TRDJ. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005;52(8):2313–22. https://doi.org/10.1002/art.21278.CrossRefPubMed

84.

Desnues B, Macedo AB, Roussel-Queval A, Bonnardel J, Henri S, Demaria O, Alexopoulou L. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A. 2014;111(4):1497–502. https://doi.org/10.1073/pnas.1314121111.CrossRefPubMedPubMedCentral

85.

Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) Expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104(3):271–80. https://doi.org/10.1172/JCI6709.CrossRefPubMedPubMedCentral

86.

De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, Gemma S, Veglianese P, Castellaneta V, Boldrin V, Rossetti C, Chiabrando C, Forloni G, Mennini T, Fanelli R. Neuroprotective effects of Toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971–81. https://doi.org/10.2119/molmed.2012.00020.CrossRefPubMedPubMedCentral

87.

Nihon-Yanagi Y, Wakayama M, Tochigi N, Saito F, Ogata H, Shibuya K. Immunohistochemical analysis of Toll-like receptors, MyD88, and TRIF in human papillary thyroid carcinoma and anaplastic thyroid carcinoma. J Thyroid Res 2021;e4226491. https://doi.org/10.1155/2021/4226491.

88.

Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, Hochhauser E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol. 2010;48(6):1236–44. https://doi.org/10.1016/j.yjmcc.2010.02.020.CrossRefPubMed

89.

Boekholdt SM, Agema WRP, Peters RJG, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJP, Jukema JW, REgression GRowth Evaluation Statin Study Group. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107(19):2416–21. https://doi.org/10.1161/01.CIR.0000068311.40161.28.CrossRefPubMed

90.

Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109:14.12.1-14.12.10. https://doi.org/10.1002/0471142735.im1412s109.CrossRef

91.

Jia F, Chen L, Fang L, Chen W. IRAK-M deletion aggravates acute inflammatory response and mitochondrial respiratory dysfunction following myocardial infarction: a bioinformatics analysis. J Proteome. 2022;15(257):104512. https://doi.org/10.1016/j.jprot.2022.104512.CrossRef

92.

Nilsen NJ, Vladimer GI, Stenvik J, Orning MPA, Zeid-Kilani MV, Bugge M, Bergstroem B, Conlon J, Husebye H, Hise AG. A role for the adaptor proteins TRAM and TRIF in Toll-like receptor 2 signaling. J Biol Chem. 2015;290(6):3209–22.PubMedCrossRef

93.

Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine. 2010;49(1):1–9.PubMedCrossRef

94.

Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.PubMedPubMedCentralCrossRef

95.

Li Z, Nguyen TT, Valaperti A. Human cardiac fibroblasts produce pro-inflammatory cytokines upon TLRs and RLRs stimulation. Mol Cell Biochem. 2021. https://doi.org/10.1007/s11010-021-04157-7.CrossRefPubMedPubMedCentral

96.

Fukui D, Yasukawa H, Sugi Y, Oba T, Nagata T, Kyogoku S, Futamata N, Yokoyama T, Yokoyama S, Kai H, Ueno T, Kage M, Imaizumi T. Transient reduction and activation of circulating dendritic cells in patients with acute myocardial infarction. Int J Cardiol. 2012;160(3):216–9. https://doi.org/10.1016/j.ijcard.2012.06.070.CrossRefPubMed

97.

Lin L, Knowlton AA. Innate immunity and cardiomyocytes in ischemic heart disease. Life Sci. 2014;100(1):1–8.PubMedPubMedCentralCrossRef

98.

Goulopoulou S, McCarthy CG, Webb RC. Toll-like receptors in the vascular system: sensing the dangers within. Pharmacol Rev. 2016;68(1):142–67.PubMedPubMedCentralCrossRef

99.

Gao Y, Sun Y, Ercan-Sencicek AG, King JS, Akerberg BN, Ma Q, Kontaridis MI, Pu WT, Lin Z. YAP/TEAD1 complex is a default repressor of cardiac Toll-like receptor genes. Int J Mol Sci. 2021;22(13):6649. https://doi.org/10.3390/ijms22136649.CrossRefPubMedPubMedCentral

100.

Ionita MG, Arslan F, De Kleijn DP, Pasterkamp G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun. 2010;2(4):307–15.PubMedCrossRef

101.

Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M. Innate immune receptors, key actors in cardiovascular diseases. Basic to Translational Science. 2020;5(7):735–49.PubMedPubMedCentralCrossRef

102.

Yu, L.; Feng, Z. The role of Toll-like receptor signaling in the progression of heart failure. Mediat Inflamm 2018;2018.

103.

Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, Mann DL. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc. 2015;4(6): e001993. https://doi.org/10.1161/JAHA.115.001993.CrossRefPubMedPubMedCentral

104.

Katare PB, Nizami HL, Paramesha B, Dinda AK, Banerjee SK. Activation of Toll like receptor 4 (TLR4) promotes cardiomyocyte apoptosis through SIRT2 dependent P53 deacetylation. Sci Rep. 2020;10(1):19232. https://doi.org/10.1038/s41598-020-75301-4.CrossRefPubMedPubMedCentral

105.

Biemmi V, Milano G, Ciullo A, Cervio E, Burrello J, Cas MD, Paroni R, Tallone T, Moccetti T, Pedrazzini G, Longnus S, Vassalli G, Barile L. Inflammatory extracellular vesicles prompt heart dysfunction via TRL4-dependent NF-ΚB activation. Theranostics. 2020;10(6):2773. https://doi.org/10.7150/thno.39072.CrossRefPubMedPubMedCentral

106.

Sopasakis VR, Sandstedt J, Johansson M, Lundqvist A, Bergström G, Jeppsson A, Hultén LM. Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions. Int J Cardiol. 2019;293:238–47.CrossRef

107.

Tang Y, Xu Z, Chen X, Wang N, Deng X, Peng L, Chen Q, Cai H. Effects of enalapril on TLR2/NF-κB signaling pathway and inflammatory factors in rabbits with chronic heart failure. Evidence-Based Complementary and Alternative Medicine. 2021. https://doi.org/10.1155/2021/9594607.CrossRefPubMedPubMedCentral

108.

Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem. 2001;276(7):5197–203. https://doi.org/10.1074/jbc.M009160200.CrossRefPubMed

109.

Gu Y, Hu X, Ge PB, Chen Y, Wu S, Zhang XW. CTRP1 aggravates cardiac dysfunction post myocardial infarction by modulating TLR4 in macrophages. Front Immunol. 2021;12:1652.CrossRef

110.

Cai S, Rohailla S, Peng J, Zeng C, Li J, Redington A. Loss of TLR4 in a murine model of left anterior descending myocardial infarction modifies early remodeling, but does not provide long-term benefit. Int J Cardiol. 2016;212:118–20.PubMedCrossRef

111.

Parapanov R, Lugrin J, Rosenblatt-Velin N, Feihl F, Waeber B, Milano G, Vergely C, Li N, Pacher P, Liaudet L. Toll-like receptor 5 deficiency exacerbates cardiac injury and inflammation induced by myocardial ischaemia-reperfusion in the mouse. Clin Sci. 2015;129(2):187–98.CrossRef

112.

Hasham MG, Baxan N, Stuckey DJ, Branca J, Perkins B, Dent O, Duffy T, Hameed TS, Stella SE, Bellahcene M. Systemic autoimmunity induced by the TLR7/8 agonist resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Dis Model Mech. 2017;10(3):259–70.PubMedPubMedCentralCrossRef

113.

Feng Y, Chen H, Cai J, Zou L, Yan D, Xu G, Li D, Chao W. Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signaling. J Biol Chem. 2015;290(44):26688–98.PubMedPubMedCentralCrossRef

114.

Pagni PP, Traub S, Demaria O, Chasson L, Alexopoulou L. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity. 2010;43(4):275–87.PubMedCrossRef

115.

Fang L, Gao X-M, Moore X-L, Kiriazis H, Su Y, Ming Z, Lim YL, Dart AM, Du X-J. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J Mol Cell Cardiol. 2007;43(5):535–44.PubMedCrossRef

116.

Becher PM, Hinrichs S, Fluschnik N, Hennigs JK, Klingel K, Blankenberg S, Westermann D, Lindner D. Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor. PLoS ONE. 2018;13(3): e0193844.PubMedPubMedCentralCrossRef

117.

de Kleijn DP, Chong SY, Wang X, Yatim SMJ, Fairhurst A-M, Vernooij F, Zharkova O, Chan MY, Foo RS, Timmers L. Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2019;115(12):1791–803.PubMedCrossRef

118.

Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med. 2013;45(2): e11. https://doi.org/10.1038/emm.2013.28.CrossRefPubMedPubMedCentral

119.

Prescott JA, Mitchell JP, Cook SJ. Inhibitory feedback control of NF-κB signalling in health and disease. Biochem J. 2021;16(478):2619–64.CrossRef

120.

Saxena A, Shinde AV, Haque Z, Wu YJ, Chen W, Su Y, Frangogiannis NG. The role of interleukin receptor associated kinase (IRAK)-M in regulation of myofibroblast phenotype in vitro, and in an experimental model of non-reperfused myocardial infarction. J Mol Cell Cardiol. 2015;89:223–31.PubMedPubMedCentralCrossRef

121.

Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013;43(9):986–95.PubMedPubMedCentralCrossRef

122.

Parizadeh SM, Ghandehari M, Heydari-Majd M, Seifi S, Mardani R, Parizadeh SM, Ghayour-Mobarhan M, Ferns GA, Hassanian SM, Avan A. Toll-like receptors signaling pathways as a potential therapeutic target in cardiovascular disease. Curr Pharm Des. 2018;24(17):1887–98.PubMedCrossRef

123.

Juntang L, Vijay K, Xinjie L. Essential roles of Toll-like receptors in atherosclerosis. Curr Med Chem. 2016;23(5):431–54.CrossRef

124.

Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased Toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;23(2):228–35.PubMedCrossRef

125.

Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL. Modulating Toll-like receptor mediated signaling by (1→ 3)-β-D-glucan rapidly induces cardioprotection. Cardiovasc Res. 2004;61(3):538–47.PubMedCrossRef

126.

Sun Y, Huang J, Song K. BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med. 2015;10(6):2319–24. https://doi.org/10.3892/etm.2015.2789.CrossRefPubMedPubMedCentral

127.

Ramirez-Carracedo R, Tesoro L, Hernandez I, Diez-Mata J, Piñeiro D, Hernandez-Jimenez M, Zamorano JL, Zaragoza C. Targeting TLR4 with ApTOLL improves heart function in response to coronary ischemia reperfusion in pigs undergoing acute myocardial infarction. Biomolecules. 2020;10(8):1167. https://doi.org/10.3390/biom10081167.CrossRefPubMedCentral

128.

Fujiwara M, Matoba T, Koga JI, Okahara A, Funamoto D, Nakano K, Tsutsui H, Egashira K. Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia–reperfusion injury by inhibiting monocyte-mediated inflammation in mice. Cardiovasc Res. 2019;115(7):1244–55. https://doi.org/10.1093/cvr/cvz066.CrossRefPubMed

129.

Louwe MC, Karper JC, de Vries MR, Nossent AY, Bastiaansen AJNM, van der Hoorn JWA, van Dijk KW, Rensen PCN, Steendijk P, Smit JWA, Quax PHA. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Int J Cardiol. 2014;176(3):788–93. https://doi.org/10.1016/j.ijcard.2014.07.086.CrossRefPubMed

130.

Zaafan MA, Abdelhamid AM. The cardioprotective effect of astaxanthin against isoprenaline-induced myocardial injury in rats: involvement of TLR4/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2021;25(11):4099–105.PubMed

131.

Shi H, Zhou P, Gao G, Liu PP, Wang SS, Song R, Zou YY, Yin G, Wang L. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem. 2021;45(7): e13757. https://doi.org/10.1111/jfbc.13757.CrossRefPubMed

132.

Sun JH, Yang HX, Yao TT, Li Y, Ruan L, Xu GR, Zhang C, Guo GX, Li AY. Gentianella acuta prevents acute myocardial infarction induced by isoproterenol in rats via inhibition of galectin-3/TLR4/MyD88/NF-кB inflammatory signalling. Inflammopharmacology. 2021;29(1):205–19.PubMedCrossRef

133.

Wang X, Guo D, Li W, Zhang Q, Jiang Y, Wang Q, Li C, Qiu Q, Wang Y. Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure. J Cell Mol Med. 2020;24(18):10677–92. https://doi.org/10.1111/jcmm.15688.CrossRefPubMedPubMedCentral

134.

Chen F, Chen ZQ, Zhong GL, Zhu JJ. Nicorandil inhibits TLR4/MyD88/NF-κB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction. Exp Biol Med. 2021;246(17):19381947. https://doi.org/10.1177/15353702211013444.CrossRef

135.

Abdelzaher WY, Ahmed SM, Welson NN, Alsharif KF, Batiha GES, Labib DAA. Dapsone ameliorates isoproterenol-induced myocardial infarction via Nrf2/HO-1; TLR4/TNF-α signaling pathways and the suppression of oxidativestress, inflammation, and apoptosis in rats. Front Pharmacol. 2021;12:1230. https://doi.org/10.3389/fphar.2021.669679.CrossRef

136.

Li H, Yang H, Wang D, Zhang L, Ma T. Peroxiredoxin2 (Prdx2) reduces oxidative stress and apoptosis of myocardial cells induced by acute myocardial infarction by inhibiting the TLR4/nuclear factor kappa B (NF-κB) signaling pathway. Med Sci Monit. 2020;26:e926281–91. https://doi.org/10.12659/MSM.926281.CrossRefPubMedPubMedCentral

137.

Cao Z, Ren D, Ha T, Liu L, Wang X, Kalbfleisch J, Gao X, Kao R, Williams D, Li C. CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling. Biochim Biophys Acta. 2013;1832(1):96–104.PubMedCrossRef

138.

Yonebayashi S, Tajiri K, Murakoshi N, Xu D, Li S, Feng D, Okabe Y, Yuan Z, Song Z, Aonuma K, Shibuya A. MAIR-II deficiency ameliorates cardiac remodelling post-myocardial infarction by suppressing TLR9-mediated macrophage activation. J Cell Mol Med. 2020;24(24):14481–90.PubMedPubMedCentralCrossRef

139.

Savoji H, Mohammadi MH, Rafatian N, Toroghi MK, Wang EY, Zhao Y, Korolj A, Ahadian S, Radisic M. Cardiovascular disease models: a game changing paradigm in drug discovery and screening. Biomaterials. 2019;198:3–26.PubMedCrossRef

140.

Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JCG. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2006;24(23):5027–35. https://doi.org/10.1016/j.vaccine.2006.03.064.CrossRefPubMed

141.

Reiter MJ, Man TLT, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55(2):234–40. https://doi.org/10.1002/jlb.55.2.234.CrossRefPubMed

142.

Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9. https://doi.org/10.1056/NEJM199110243251703.CrossRefPubMed

143.

Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014;37(2):84–92.PubMedCrossRef

144.

Tilea I, Varga A, Serban RC. Past, present, and future of blood biomarkers for the diagnosis of acute myocardial infarction—promises and challenges. Diagnostics (Basel). 2021;11(5):881. https://doi.org/10.3390/diagnostics11050881.CrossRef

145.

Wu Y, Pan N, An Y, Xu M, Tan L, Zhang L. Diagnostic and prognostic biomarkers for myocardial infarction. Front Cardiovasc Med 2022, 7, Accessed: [Online]. https://www.frontiersin.org/article/, https://doi.org/10.3389/fcvm.2020.617277

146.

Zhang S, Liu W, Liu X, Qi J, Deng C. Biomarkers identification for acute myocardial infarction detection via weighted gene co-expression network analysis. Medicine (Baltimore). 2017;96(47): e8375. https://doi.org/10.1097/MD.0000000000008375.CrossRef

147.

Zhang P, Shao L, Ma J. Toll-Like receptors 2 and 4 predict new-onset atrial fibrillation in acute myocardial infarction patients. Int Heart J. 2018;59(1):64–70. https://doi.org/10.1536/ihj.17-084.CrossRefPubMed

148.

Shao L, Zhang P, Zhang Y, Lu Q, Ma A. TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients. Heart Vessels. 2014;29(5):690–8. https://doi.org/10.1007/s00380-013-0421-3.CrossRefPubMed

149.

Bhagat S, Biswas I, Alam MI, Khan M, Khan GA. Key role of extracellular RNA in hypoxic stress induced myocardial injury. PLoS ONE. 2021;16(12): e0260835. https://doi.org/10.1371/journal.pone.0260835.CrossRefPubMedPubMedCentral

150.

Mirzaoglu C, Kivrak T, Balin M, Kobat MA, Dogdu O, Karaca I. Is there a correlation between systolic heart failure and levels of toll-like receptor-5 and N-terminal pro-B-type natriuretic peptide? Int J Cardiovasc Acad. 2018;4(4):65. https://doi.org/10.4103/IJCA.IJCA_41_18.CrossRef

151.

Huang Z, Liu Y, Liang L, Liu W, Sooranna SR, Mo J, Liu L, Li Z, Li K, Guo J. Correlation between coronary stenosis and Toll-like receptors 2 and 4 levels in Chinese Zhuang patients with coronary heart disease. Exp Ther Med. 2019;18(3):2346–52. https://doi.org/10.3892/etm.2019.7805.CrossRefPubMedPubMedCentral

152.

Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GYH. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med. 2013;273(3):294–305. https://doi.org/10.1111/joim.12011.CrossRefPubMed

153.

Bochaton T, Paccalet A, Jeantet P, Crola Da Silva C, Cartier R, Prieur C, Jossan C, Bonnefoy-Cudraz E, Mewton N, Ovize M. Heat shock protein 70 as a biomarker of clinical outcomes after STEMI. J Am Coll Cardiol. 2020;75(1):122–4.PubMedCrossRef

154.

Savas G, Kalay N, Altin P, Dursun GK, Cetin M, Aytekin M. Hyaluronan as a promising biomarker for myocardial damage. Tohoku J Exp Med. 2019;248(2):99–106.PubMedCrossRef

155.

Li X, Guo D, Chen Y, Hu Y. Toll-like receptors/TNF-α pathway crosstalk and impact on different sites of recurrent myocardial infarction in elderly patients. Biomed Res Int. 2022. https://doi.org/10.1155/2022/1280350.CrossRefPubMedPubMedCentral

156.

Li M, Chen F, Zhang Y, Xiong Y, Li Q, Huang H. Identification of post-myocardial infarction blood expression signatures using multiple feature selection strategies. Front Physiol 2020;483. https://doi.org/10.3389/fphys.2020.00483.

157.

Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, Wei Q. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7(1):1–38. https://doi.org/10.1038/s41392022-00925.CrossRef

158.

Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol. 2016;94:189–200.PubMedCrossRef

Titel: Potential therapeutic strategies for myocardial infarction: the role of Toll-like receptors
verfasst von: Sumra Komal
Nimrah Komal
Ali Mujtaba
Shu-Hui Wang
Li-Rong Zhang
Sheng-Na Han
Publikationsdatum: 24.05.2022
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 5/2022
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-022-09290-z

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Potential therapeutic strategies for myocardial infarction: the role of Toll-like receptors

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Effect of different cytokines in combination with IL-15 on the expression of activating receptors in NK cells of patients with Behçet’s disease

Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome

Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis

Livin promotes Th2-type immune response in airway allergic diseases

High mobility group box 1 (HMGB1) inhibition attenuates lipopolysaccharide-induced cognitive dysfunction and sickness-like behavior in mice

Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO